TearSolutions Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $766K

  • Investors
  • 13

TearSolutions General Information

Description

Developer of a peptide therapy designed to treat corneal and ocular surface diseases. The company offers a stable peptide that replicates the biological activity of a naturally occurring tear protein to repair corneal epithelium and sensory neurons, enabling ophthalmologists and eye care providers to promote corneal regeneration and improve ocular surface healing.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 315 Old Ivy Way
  • Suite 301
  • Charlottesville, VA 22903
  • United States
+1 (434)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • 315 Old Ivy Way
  • Suite 301
  • Charlottesville, VA 22903
  • United States
+1 (434)

TearSolutions Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TearSolutions Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 01-Aug-2026 $766K Completed Generating Revenue
6. Later Stage VC (Series B) 21-Nov-2024 Completed
5. Later Stage VC 24-Jan-2022 Completed
4. Later Stage VC (Series B2) 26-Feb-2020 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 06-Dec-2017 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 10-Nov-2015 $3M $3M Completed Startup
1. University Spin-Out 01-Jan-2013 Completed Startup
To view TearSolutions’s complete valuation and funding history, request access »

TearSolutions Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-3-3
Series B-3-2
Series B-3-1
Series B-2-1
Series B2
Series B-1-1
Series B1
Series A-1 642,906 $0.001000 8% $5 $5 1x $5 2.34%
Series A 642,906 $0.001000 8% $5 $5 1x $5 2.34%
To view TearSolutions’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

TearSolutions Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a peptide therapy designed to treat corneal and ocular surface diseases. The company offers a stable peptid
Drug Discovery
Charlottesville, VA
10 As of 2025

Cambridge, United Kingdom
 

Watertown, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TearSolutions Competitors (12)

One of TearSolutions’s 12 competitors is Foventa Therapeutics, a Venture Capital-Backed company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Foventa Therapeutics Venture Capital-Backed Cambridge, United Kingdom
EyePoint Corporation Watertown, MA
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
Genentech Formerly VC-backed South San Francisco, CA
PulseSight Therapeutics Venture Capital-Backed Paris, France
You’re viewing 5 of 12 competitors. Get the full list »

TearSolutions Patents

TearSolutions Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023300970-A1 Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms Pending 01-Jul-2022
EP-4547221-A2 Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms Pending 01-Jul-2022
EP-4547221-A4 Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms Pending 01-Jul-2022
US-20260021159-A1 Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms Pending 01-Jul-2022
WO-2024006653-A2 Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms Inactive 01-Jul-2022 A61K38/10
To view TearSolutions’s complete patent history, request access »

TearSolutions Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TearSolutions Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Angel (individual) Minority
Virginia Innovation Partnership Corporation Not-For-Profit Venture Capital Minority
UVA LVG Seed Fund Venture Capital Minority
CAV Angels Angel Group Minority
You’re viewing 5 of 13 investors. Get the full list »

TearSolutions FAQs

  • When was TearSolutions founded?

    TearSolutions was founded in 2013.

  • Where is TearSolutions headquartered?

    TearSolutions is headquartered in Charlottesville, VA.

  • What is the size of TearSolutions?

    TearSolutions has 10 total employees.

  • What industry is TearSolutions in?

    TearSolutions’s primary industry is Drug Discovery.

  • Is TearSolutions a private or public company?

    TearSolutions is a Private company.

  • What is TearSolutions’s current revenue?

    The current revenue for TearSolutions is .

  • How much funding has TearSolutions raised over time?

    TearSolutions has raised $44.1M.

  • Who are TearSolutions’s investors?

    , , Virginia Innovation Partnership Corporation, UVA LVG Seed Fund, and CAV Angels are 5 of 13 investors who have invested in TearSolutions.

  • Who are TearSolutions’s competitors?

    Foventa Therapeutics, EyePoint, ONL Therapeutics, Genentech, and PulseSight Therapeutics are some of the 12 competitors of TearSolutions.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process